Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Zalcitabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | PDE3A | Q14432 | 3/20 | 0.62 |
| ▸ | ALB | P02768 | 3/20 | 0.62 |
| ▸ | CACNA1F | O60840 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | CACNA1D | Q01668 | 2/20 | 0.62 |
| ▸ | CACNA1S | Q13698 | 2/20 | 0.62 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.58 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.54 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.54 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.54 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.51 |
| ▸ | POLG | P54098 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Zalcitabine SCHEMBL21100417 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL10380711 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL598496 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL3715526 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL9194365 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL3598 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL12149465 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL8094882 | 1.00 | LMNA (0.62) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL27555151 | 0.99 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT | |
| Zalcitabine SCHEMBL29277683 | 0.99 | LMNA (0.60) | LMNAPDE3AALBCACNA1FMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0550646-B1 | IMPROVED NUCLEIC ACID SEQUENCE ANALYSIS WITH NUCLEOSIDE-5'-0-(1-THIOTRIPHOSPHATES) | PERKIN ELMER CORP (US) | 2000-04-05 | — | — | EP | claimed |
| EP-0500779-B1 | 4,7-DICHLOROFLUORESCEIN DYES AS MOLECULAR PROBES | PERKIN ELMER CORP (US) | 1999-04-21 | — | — | EP | claimed |
| CN-116157152-A | Compositions and methods for improving the efficacy of a drug | 赫利昂生物股份有限公司 | 2023-05-23 | — | — | CN | disclosed |
| EP-3675838-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | Puretecch LYT, Inc. (US) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019046491-A1 | LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS | ARIYA THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| CN-106559991-A | Heteroaryl compounds for kinase inhibition | 阿里亚德医药股份有限公司 | 2017-04-05 | — | — | CN | disclosed |
| EP-2922572-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB Science (FR) | 2015-09-30 | — | — | EP | disclosed |
| WO-2014079709-A1 | USE OF SMALL MOLECULE INHIBITORS/ACTIVATORS IN COMBINATION WITH (DEOXY)NUCLEOSIDE OR (DEOXY)NUCLEOTIDE ANALOGS FOR TREATMENT OF CANCER AND HEMATOLOGICAL MALIGNANCIES OR VIRAL INFECTIONS | AB SCIENCE (FR) | 2014-05-30 | — | — | WO | disclosed |
| WO-2013076586-A2 | SYSTEMS, METHODS, AND COMPUTER PROGRAM PRODUCTS FOR GUIDING THE SELECTION OF THERAPEUTIC TREATMENT REGIMENTS | ADVANCED BIOLOGICAL LABORATORIES SA (LU) | 2013-05-30 | — | — | WO | disclosed |
| US-7838006-B2 | Viral vaccine composition, process and methods of use | IMMUNITOR USA INC. (US) | 2010-11-23 | — | — | US | disclosed |
| US-20100130439-A1 | GENOMIC MUTATION INHIBITORS THAT INHIBIT Y FAMILY DNA POLYMERASES | DEFENSE THREAT REDUCTION AGENCY/BC | 2010-05-27 | — | — | US | disclosed |
| US-6451973-B1 | HUMAN IMMUNODEFICIENCY VIRUS (HIV) PROTEASE INHIBITORS | NOVATIS AG (CH) | 2002-09-17 | — | — | US | disclosed |
| EP-0708085-B1 | Antiviral ethers of aspartate protease substrate isosteres | NOVARTIS AG (CH) | 2002-07-17 | — | — | EP | disclosed |
| EP-0876336-B1 | AZAHEXANE DERIVATIVES AS SUBSTRATE ISOSTERS OF RETROVIRAL ASPARATE PROTEASES | NOVARTIS AG (CH) | 2002-06-05 | — | — | EP | disclosed |
| EP-0915841-B1 | ANILINOPEPTIDE DERIVATIVES | NOVARTIS AG (CH) | 2002-02-27 | — | — | EP | disclosed |
| US-6300519-B1 | REACTING HYDRAZINE DERIVATIVE WITH EPOXIDE COMPOUND | NOVARTIS FINANCE CORPORATION | 2001-10-09 | — | — | US | disclosed |
| US-6225345-B1 | FOR THERAPY OF ACQUIRED IMMUNODEFICIENCY SYNDROME | NOVARTIS AG (CH) | 2001-05-01 | — | — | US | disclosed |
| US-5849911-A | Antivirally active heterocyclic azahexane derivatives | NOVARTIS FINANCE CORPORATION (US) | 1998-12-15 | — | — | US | disclosed |
| CN-1132756-A | Antiviral ethers of aspartate protease substrate isosteres | CIBA GEIGY AG (CH) | 1996-10-09 | — | — | CN | disclosed |
| EP-0708085-A2 | Antiviral ethers of aspartate protease substrate isosteres | CIBA-GEIGY AG (CH) | 1996-04-24 | — | — | EP | disclosed |